Home Overview Press Room Blog Publications For Students about us
Search

Medical Gene Transfer : Displaying 86-95 of 132


Picking Nits or Learning Lessons?Defensiveness on Display in Gene Therapy Death by Marcy Darnovsky and Osagie K. ObasogieBioethics Forum September 17th, 2007The full story of a recent death in a gene therapy clinical trial is still unfolding. But there's a fair amount we do know, and much of it is troubling. Some gene therapy insiders have tried to diminish its significance by characterizing it as an unfortunate aspect of medical progress.
Targeted Genetics consent documentResearch subject information and consent form Jolee Mohr, a 36-year-old Illinois resident, was given this 15-page document before participating in a gene therapy experiment. She died on July 24, 2007, shortly after her second injection with the gene transfer product.
Gene Therapy Death Raises Ethical Issuesby Marcy DarnovskySan Francisco ChronicleSeptember 13th, 2007The recent death of a research subject in a gene therapy clinical trial raises critical, and troubling, questions.
The Empire Strikes Backby Osagie Obasogie Biopolitical TimesAugust 28th, 2007One would hope and expect that Jolee Mohr’s recent death during a gene therapy clinical trial would give pause to the field’s researchers as well as the multi-billion dollar clinical trial industry. But the response has been surprisingly defiant.
Fungus Infected Woman Who Died After Gene Therapyby Rick WeissWashington PostAugust 20th, 2007The 36-year-old Illinois woman who died last month after being treated with an experimental gene therapy was infected with a fungus that usually causes only a mild illness.
Biotechnology Appeals to Our Lizard Brainsby Jesse ReynoldsBiopolitical TimesAugust 17th, 2007Will technologies with enormous power to reshape both society and individuals be initially introduced for frivolous purposes? Will pet cloning and gene therapy for sexual confidence make human reproductive cloning and genetic modification technically feasible and more palatable?
Gene Therapy Risky Business for Patientsby Osagie K. ObasogieSeattle Post-Intelligencer August 16th, 2007Jolee Mohr, a vibrant 36-year-old mother, recently died while participating in a gene therapy clinical trial for arthritis run by the Seattle-based biotech firm. Why is an unproven procedure linked to multiple deaths being tested on people with non-fatal illnesses?
Medical Professor Defends Gene-Therapy Trial in Which a Patient Diedby By Lila GutermanChronicle of Higher EducationAugust 13th, 2007After a patient died last month in a clinical trial of gene therapy for rheumatoid arthritis, accusations appeared in the news media that she had not been adequately protected from the risks of experimentation on human beings. But last week, a professor at Northwestern University who was involved in the study defended the procedures.
Public Interest Group Calls for Public Disclosures in Gene Therapy DeathAugust 8th, 2007Troubling new revelations have emerged this week in the death of an Illinois woman in a gene therapy trial for arthritis, prompting the Center for Genetics and Society to call on the federal government to consider firmer regulatory action.
Death Points to Risks in Research: One Woman's Experience in Gene Therapy Trial Highlights Weaknesses in the Patient Safety Net[Quotes CGS's Marcy Darnovsky] by Rick WeissWashington PostAugust 6th, 2007Jolee Mohr died from massive bleeding and organ failure July 24, leaving behind a 5-year-old daughter and a host of questions about why she was recruited into a gene therapy experiment whose chief goal was to test the safety of a novel arthritis treatment that had virtually no chance of helping her.
Displaying 86-95 of 132  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760